VentrAssist® LVAD market potential

There are an estimated 11.2 million sufferers of congestive heart failure worldwide, which is increasing by 10 per cent each year. Of these people, an estimated one million have a life expectancy of less than one year. Each year, only about 3,000 people receive a heart transplant as the only current definitive long-term treatment for end-stage congestive heart failure. At the same time, organ donations are decreasing.

Europe and the United States represent a significant proportion of the market for congestive heart failure therapy.

Ventracor’s primary focus is to deliver the VentrAssist® LVAD to the global market.